Vera Therapeutics Inc. | Small-cap | Healthcare
$23.31
3.23%
| Vera Therapeutics Stock Comparison:
Vera Therapeutics vs VertexVera Therapeutics vs RegeneronVera Therapeutics vs Immunocore HoldingsVera Therapeutics vs AgiosVera Therapeutics vs Amicus TherapeuticsVera Therapeutics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 0
Operating Income -167.2M
Net Income -152.1M
EPS (Diluted) -$2.75

Balance Sheet Metrics

Total Assets 655.7M
Total Liabilities 78.5M
Shareholders Equity 577.2M
Debt to Equity 0.14

Cash Flow Metrics

Operating Cash Flow -133.9M
Free Cash Flow -135.7M

Revenue & Profitability Trend

Vera Therapeutics Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 0 0 0 0 0
Cost of Goods Sold - - - - -
Gross Profit - - - - -
Operating Expenses 167.2M 102.0M 90.9M 34.4M 49.2M
Operating Income -167.2M -102.0M -90.9M -34.4M -49.2M
Pre-tax Income -152.1M -96.0M -89.1M -32.6M -53.4M
Income Tax 1.0K 1.0K 1.0K 1.0K 1.0K
Net Income -152.1M -96.0M -89.1M -32.6M -53.4M
EPS (Diluted) -$2.75 -$2.25 -$3.35 -$2.43 -$13.10

Income Statement Trend

Vera Therapeutics Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 651.2M 172.0M 125.7M 82.5M 54.3M
Non-Current Assets 4.5M 3.5M 5.7M 1.2M 293.0K
Total Assets 655.7M 175.5M 131.4M 83.7M 54.6M
Liabilities
Current Liabilities 25.4M 22.3M 25.6M 7.7M 2.4M
Non-Current Liabilities 53.2M 51.6M 28.9M 6.5M 141.5M
Total Liabilities 78.5M 73.9M 54.5M 14.2M 143.9M
Equity
Total Shareholders Equity 577.2M 101.7M 76.9M 69.6M -89.3M

Balance Sheet Composition

Vera Therapeutics Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -152.1M -96.0M -89.1M -32.6M -53.4M
Operating Cash Flow -133.9M -90.2M -67.3M -25.0M -36.0M
Investing Activities
Capital Expenditures -972.0K -63.0K -62.0K 0 -42.0K
Investing Cash Flow -425.0M -39.4M -70.6M -5.0M -42.0K
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 593.3M 132.5M 99.8M 53.3M 85.1M
Free Cash Flow -135.7M -92.2M -67.7M -23.7M -34.9M

Cash Flow Trend

Vera Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -8.41
Forward P/E -6.96
Price to Book 2.58
PEG Ratio -6.96

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -39.49%
Return on Assets -23.46%

Financial Health

Current Ratio 27.68
Debt to Equity 10.18
Beta 1.13

Per Share Data

EPS (TTM) -$3.00
Book Value per Share $8.39
Revenue per Share $0.00

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
vera 1.4B -8.41 2.58 -39.49% 0.00% 10.18
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Immunocore Holdings 1.6B -31.41 4.13 -5.86% -6.48% 114.67
Agios 1.9B 2.89 1.32 60.26% 1,798.26% 3.61
Amicus Therapeutics 1.8B -31.56 9.08 -18.12% -5.41% 229.11

Financial data is updated regularly. All figures are in the company's reporting currency.